The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
This preferential treatment harms independent pharmacies and ... there has traditionally been a lack of uptake in biosimilars on PBM formularies, likely due to less favorable PBM rebate models ...
The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...
Based on conversations with industry expects, the Act, while incremental, does not include any adverse new ideas that would materially harm PBM profits, and the text allows enough room and time ...
Ron Wyden says Elon Musk, an advisor to President Donald Trump who's on track to lead a new Department of Government Efficiency, pushed the PBM provisions out of the package. The new American ...
The Conversation on MSN19d
What are pharmacy benefit managers? A health economist explainsPharmacy benefit managers started popping up in the late 1960s as providers of claims processing and administrative services ...
"They're helping patients kind of manage through the treatment paradigm with respect to which drugs to take, which formulary drugs are on, and kind of managing that whole process. So there is a ...
The PBM changes would put guardrails on the business practices of the industry, something that’s been a bipartisan priority for years but, until now, never made it to the finish. The package ...
“PBM tactics inflate American’s prescription drug costs, force pharmacy closures, and block access to Americans’ pharmacies of choice. The work done by Congress in the 118th Congress and in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback